The reason for the high frequency of depression and anxiety in Parkinson's disease is poorly
understood. Degeneration of neurotransmitter systems other than dopamine might play a …

Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective
in Parkinson's disease (PD), and a pilot clinical study using 18 F‐dopa positron emission …

In 1992 the Core Assessment Program for Intracerebral Transplantations (CAPIT) was published
providing the minimal requirements for a common patient evaluation protocol. Despite …

Background Huntington's disease is a neurodegenerative disease of genetic origin that mainly
affects the striatum. It has severe motor and cognitive consequences and, up to now, no …

Background Parkinson's disease is typically treated with oral dopamine replacement therapies;
however, long-term treatment leads to motor complications and, occasionally, impulse …

Background Long-term immunosuppressive treatment does not efficiently prevent relapses
of lupus nephritis (LN). This investigator-initiated randomised trial tested whether …

Background Although we have shown in three out of five patients with Huntington's disease
that motor and cognitive improvements 2 years after intracerebral fetal neural grafts are …

Two parkinsonian patients who experienced transient hypomanic states when the
subthalamic nucleus (STN) was stimulated during postoperative adjustment of the electrical …

Previous research suggests that patients with Alzheimer's disease (AD) are impaired on
executive function early in the course of disease, but negative findings were reported. To …

Astrocytes and microglia become reactive under most brain pathological conditions, making
this neuroinflammation process a surrogate marker of neuronal dysfunction. …